Archive for September 2020
GVN 2020 Special Annual Meeting Executive Summary
A New Era in the Fight Against COVID-19 Pandemic: Forging a “Viral Pandemic Readiness Alliance” A September 22-23, 2020 Special Meeting of Top Global Experts Launches “Global Virus Network’s Vision for Future Pandemic Preparedness” We are in the midst of a pandemic that has completely upended the world with major economic, social and psychological impacts.…
Read MoreGVN’s Top Virus Experts Meet Together To Identify Most Promising Advances To Battle COVID-19 & Strategies To Prepare For Future Pandemics
Rapid Diagnostic Testing, Repurposing Drug Therapies and Vaccines Targeting Innate Immunity, Are Integral Factors in Mitigating COVID-19 Baltimore, Maryland, USA, September 30, 2020: The Global Virus Network (GVN), a coalition of the world’s leading medical and basic virology research centers working to prevent illness and death from viral disease, convened a press conference with attendees…
Read MoreGlobal Virus Network International Press Conference September 24, 2020
GVN 2020 Meeting Press Release GVN 2020 Special Annual Meeting Executive Summary
Read MoreGlobal Virus Network (GVN) Presents Doherty Institute Director, University of Melbourne Professor Sharon Lewin with the Robert C. Gallo Award for Scientific Excellence and Leadership in Medical Virology
Baltimore, Maryland, USA, September 22, 2020: The Global Virus Network (GVN), comprising foremost experts around the world in every class of virus-causing disease in humans and some animals, today presented Doherty Institute Director, University of Melbourne Professor Sharon Lewin with the Robert C. Gallo Award for Scientific Excellence and Leadership in Medical Virology Presented today…
Read MoreCurrent Status of COVID-19 Vaccine Development
As the COVID-19 pandemic expands, interests in the progress of vaccine development are intensifying. Despite an unprecedented rate of progress, it is still uncertain when a safe, effective vaccine will be available for wide distribution to the public. Successful vaccine development goes through a series of stages, from animal studies for the evaluation of its…
Read MoreGlobal Virus Network Announces 2020 Special Annual Meeting
World-Renowned Scientists Come Together to Address COVID-19, Ramifications for Future Epidemics and Pandemics at September 22-23 Virtual Meeting Editors’ note: Media are invited to participate in a virtual press conference on Thursday, September 24 at 9 am ET, which will highlight key outcomes/findings of the meeting. GVN founders and session chairs will present the findings,…
Read MoreAbbott partners with the Global Virus Network on a new coalition to prepare for future pandemics
In late 2019, a group of infectious disease experts had an idea— to create a coalition among leaders in the public and private sectors that could help prepare for how the global health community responds to emerging pandemics and collaborate to end major viral pandemics. As the initial program formed between Abbott and Global Virus…
Read MoreCOVID-19 Vs. Influenza: Influenza Vaccination Amid COVID-19 Pandemic
Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), a highly contagious virus, emerged in 2019 from Wuhan, China (1). It rapidly spread around the world causing a novel acute respiratory disease, coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020. Consequently, the current COVID-19 pandemic impacts global health and…
Read MoreProminent Australian and Russian Research Institutions Join Global Virus Network to Combat Viral Diseases
Center for Emerging Viruses, Inflammation and Therapeutics of the Menzies Health Institute Queensland (MHIQ) at Griffith University, Australia and the Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences Join GVN at Critical Time for Information Sharing Baltimore, Maryland, USA, September 8, 2020: The Global…
Read MoreWill Neutralizing and Therapeutic Antibodies Play a Role in the Treatment of COVID-19?
Interest has increasingly been focused on the potential of virus-neutralizing monoclonal antibodies (mAbs) to treat COVID-19 by passive immunization. These antibodies generally target the viral spike protein to prevent infection by blocking ACE2 receptor binding to its receptor binding domain (RBD). There are several issues, however, that need to be addressed to determine when and…
Read More